An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...
Forbes contributors publish independent expert analyses and insights. Andrew Pulrang writes about disability practices, policy, and culture. Disability activism is empowering. For some disabled people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results